2021 AUA Annual Meeting Highlights: Prostate Cancer

To better understand the educational needs of urologists related to the treatment of advanced prostate cancer, the AUA conducted Phase I of an in-depth educational needs assessment of its domestic membership representing over 90% of U.S. Board Certified Urologists in 2013. The results from the study highlighted educational gaps in relation to the sequencing of agents, managing the side effects of treatment and management of comorbid conditions, as well as the need for a thorough review of the AUA’s Castration Resistant Prostate Cancer (CRPC) Clinical Guideline.


The AUA Office of Education thanks the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

  • Astellas
  • Exact Sciences Corporation
  • Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Urologists in training
  • Non-physician providers involved in urology

Learning Objectives

AUA Guidelines on Ad-vanced/Metastatic/Castration Resistant Prostate Cancer

At the conclusion of the activity, participants will be able to:

  • Describe sequencing and indications for active treatment with approved agents in the management of non-metatstic CRPC.
  • Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly up-dated AUA CRPC guidelines.
  • Improve diagnostic and therapeu-tic decision-making processes by illustrating the application of these guidelines in urological practice.
  • Analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer.

Highlights Summary of the State-of-the-Art Lecture on: Personalized Medicine in the Management of Prostate Cancer across the Patient Care Continuum

At the conclusion of the activity, participants will be able to:

  • Discuss personalized care for pros-tate cancer therapy including prog-nostic versus predictive markers, potential predictive markers and prospective trials, as well as barriers.

Incorporating Genomic Testing for Prostate Cancer into Your Practice

At the conclusion of the activity, participants will be able to:

  • Describe the seminal validation stud-ies for prostate cancer genomic test-ing.
  • List the different prognostic end-points provided by various genomic tests.
  • Identify appropriate genomic testing based on a patient’s unique clinical characteristics.
  • Review the AUA and National Com-prehensive Cancer Network® guide-lines for genomic testing for prostate cancer.

Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease, & CRPC

At the conclusion of the activity, participants will be able to:

  • Counsel men with BRCA1/2 mu-tations, Lynch syndrome and other key inherited syndromes regarding their prostate cancer risk and appro-priate strategies for cancer screening.
  • Identify the criteria for genetic test-ing of prostate cancer patients, the gene panels available and options for testing these men.
  • Interpret results of genetic testing and relay this information to patients in order to facilitate shared decision making based on the test results.
  • Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, in-cluding recommendations regarding PARP-inhibition, chemotherapy and immunotherapy.

Common Dilemmas in Prostate Cancer Detection and Management

At the conclusion of the activity, participants will be able to:

  • Optimally use prostate specific anti-gen (PSA) and other biomarkers to minimize unnecessary testing and biopsy when screening men who are at average risk for prostate cancer.
  • Apply the principles of “risk-adapt-ed” screening for men at elevated risk for prostate cancer based on race, family history, early in life PSA, polygenic risk scores and specific genetic mutations (eg BRCA1/2).
  • Identify the roles of MRI, high frequency ultrasound and novel transperineal approaches to improve prostate biopsy.
  • Treat men with locally advanced prostate cancer with multimodal approaches and how to choose and sequence hormonal, chemotherapeutic, immunologic and/or targeted approaches (eg PARP inhibitors) in men with metastatic and castrate resistant prostate cancer.
  • Explain how to choose and sequence secondary and tertiary hormonal, chemotherapeutic, immunologic and/or targeted therapies (eg PARP inhibitors) in men with metastatic and castrate resistant prostate cancer.

What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer: A Case-Based Session for Urologists, Advanced Practice Providers and Teams

At the conclusion of the activity, participants will be able to:

  • List the 3 main advanced prostate cancer disease states (HSMPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urological practice.
  • Identify FDA-approved hormonal and nonhormonal therapies for use in each of these 3 disease states: HSMPC, M0 CRPC, M1 CRPC.
  • Demonstrate the safe use and unique mechanism of action and side effects of new and existing agents. Explain the sequencing of novel therapies and be able to identify pa-tient progression of disease by PSA, imaging, and signs and symptoms. Work in team care including urolo-gists, advanced practice providers, oncology nursing, oncology pharma-cy, medical oncology and radiation oncology and their support staffs

Advanced Prostate Cancer

At the conclusion of the activity, participants will be able to:

  • Assess current approaches and explore new strategies for clinical management of advanced prostate cancer.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Course opens: 
Course expires: 

COI Review Work Group Disclsoures

PDF icon COI Review Work Group Disclosures_2021_18.pdf

Author & Editor Disclosures

PDF icon Editor and Author Disclosures_AUA Highlights_PCA.pdf

AUA Staff have nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation

To claim CME credit/hours of participation, the learner must read the content, complete the posttest, passing with 80% accuracy and submit the evaluation and credit request form.

Estimated time to complete this activity: 1.25 hours
Release Date: December 2021
Expiration Date: December 31, 2022

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments

Mitigation of Identified Conflict of Interest

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


The opinions and recommendations express by faculty, authors and other experts whos input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association. 


Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Please login or register to take this course.